Please ensure Javascript is enabled for purposes of website accessibility

Here's Why CymaBay Therapeutics Rose 109% in May

By Maxx Chatsko – Jun 9, 2020 at 5:53PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The development-stage company might be able to resume the development of its lead drug candidate, which was halted in late 2019.

What happened

Shares of CymaBay Therapeutics (CBAY 1.76%) jumped 109% last month, according to data from S&P Global Market Intelligence. The stock popped when the company reported first-quarter 2020 operating results, which were headlined by an important update on the company's lead drug candidate, seladelpar. 

Development of the experimental therapy was halted in late 2019, when researchers found evidence it might have led to liver damage in a clinical trial for primary biliary cholangitis (PBC). CymaBay Therapeutics also decided to halt development of the drug candidate in nonalcoholic steatohepatitis (NASH). 

But upon additional review of data from the halted phase 2b study in NASH, an independent panel of researchers found no evidence seladelpar induces liver damage in those patients. CymaBay Therapeutics announced in mid-May it intended to resume development of the drug candidate in NASH, which sent the small-cap stock soaring.

A businessman riding a cartoon rocketship.

Image source: Getty Images.

So what

Recent events are encouraging, but there's a catch: CymaBay Therapeutics can't resume development of seladelpar in NASH without the support of the U.S. Food and Drug Administration (FDA). 

The company claims an "independent expert panel unanimously concluded there is no clinical, biochemical, or histological evidence" that the drug candidate damages the liver of NASH patients. The panel also unanimously supported resuming development of seladelpar, which could help to persuade regulators. But investors should remain cautiously optimistic at best until the FDA officially allows the clinical trial to proceed.

Now what

CymaBay Therapeutics is a $300 million company with only three pipeline assets, which includes the halted development of seladelpar and a preclinical asset. That doesn't provide a comfortable level of risk diversification for investors. While the development-stage business ended March with $176 million in cash, the risk-reward profile doesn't appear to favor investors at this time. 

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

CymaBay Therapeutics Inc. Stock Quote
CymaBay Therapeutics Inc.
CBAY
$3.47 (1.76%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.